Collectively, these findings underscore the central role of cytokine-mediated signaling networks and inhibitory receptor upregulation in orchestrating CD8+ T cell dysfunction within TME, emphasizing the therapeutic potential of targeting these pathways to reinvigorate anti-tumor immunity. The gene discussed is CD8A; the disease is neoplasm.